Effect of ELF-EMF Exposure on Human Neuroblastoma Cell Line: a Proteomics Analysis.

Author: Hasanzadeh H1, Rezaie-Tavirani M2, Seyyedi SS3, Zali H4, Heydari Keshel S4, Jadidi M1, Abedelahi A5.
Affiliation: 1Dept. of Medical Physics, Semnan University of Medical Sciences, Semnan, Iran. 2Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3Dept. of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran. 4Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5Dept. of Anatomy, Tabriz University of Medical Sciences, Tabriz, Iran.
Conference/Journal: Iran J Cancer Prev.
Date published: 2014 Winter
Other: Volume ID: 7 , Issue ID: 1 , Pages: 22-7 , Word Count: 186


Abstract
BACKGROUND:
Extremely low frequency electromagnetic fields (ELF-EMF) have been common in daily life all over the world. They have produced by power lines and electrical appliances, but higher levels of them have raised a lot of concerns about their carcinogenesis. Both epidemiological and laboratory studies have suggested that EMFs might increase cancer incidence, including acute childhood leukemia, brain and breast cancer.
METHODS:
In the present study, SH-SY5Y human neuroblastoma cell line has exposed to 2mT, 50 Hz magnetic field for 3 h. Next, effect of this exposure on protein expression including over-expression or under-expression has assessed by proteomics.
RESULTS:
Bioinformatics and statistical analysis using progenesis same spot software on the obtained 2D electrophoresis has shown that expression of 189 proteins in exposed group has changed relative to control. Besides, PCA analysis has verified results of clustering, and has shown that protein data has clustered according to experimental conditions.
CONCLUSION:
The results of this study have shown that ELF-EMF changes cell morphology via altering protein expression, but more profound studies have needed to determine the kind of proteins altered.
KEYWORDS:
Electromagnetic fields; Neuroblastoma; Proteomics

PMID: 25250144 [PubMed] PMCID: PMC4142951